The trophoblast giant cell lineage is characterized by endoreduplication and expression of members of the PRL gene family. This report describes the functional consequences following in vitro manipulation of a rat trophoblast cell line, termed Rcho-1. Rcho-1 cells can be cultured under conditions that promote proliferation or differentiation. Proliferation is maintained by culturing the cells in the presence of fetal bovine serum under subconfluent conditions. Differentiation is induced by growing the cells to confluence and removing the mitogenic source. Differentiation is characterized by continued synthesis of DNA in the absence of proliferation (endoreduplication) and the sequential expression of members of the PRL gene family. Western and Northern blot analyses demonstrated that placental lactogen-I (PL-I) was first expressed, followed sequentially by PL-II, PRL-like protein-A, and PRL-like protein-C. The ontogeny of expression of members of the PRL gene family by the Rcho-1 cells recapitulated the pattern of in situ expression by trophoblast giant cells of the junctional zone of the chorioallantoic placenta. A notable difference between in viuo trophoblast giant cell differentiation and in vitro Rcho-1 cell differentiation is the termination of PL-I expression in normal trophoblast giant cells developing in vivo and the continued expression of PL-I in differentiated Rcho-1 cell cultures. The &ho-l cell line provides a unique in vitro model for investigating the initiation and maintenance of the trophoblast giant cell differentiation pathway. (Endocrinology 134: 2390(Endocrinology 134: -2396(Endocrinology 134: ,1994 
expressed, followed sequentially by PL-II, PRL-like protein-A, and PRL-like protein-C. The ontogeny of expression of members of the PRL gene family by the Rcho-1 cells recapitulated the pattern of in situ expression by trophoblast giant cells of the junctional zone of the chorioallantoic placenta. A notable difference between in viuo trophoblast giant cell differentiation and in vitro Rcho-1 cell differentiation is the termination of PL-I expression in normal trophoblast giant cells developing in vivo and the continued expression of PL-I in differentiated Rcho-1 cell cultures. The &ho-l cell line provides a unique in vitro model for investigating the initiation and maintenance of the trophoblast giant cell differentiation pathway. (Endocrinology 134: 2390 (Endocrinology 134: -2396 (Endocrinology 134: ,1994 T HE TROPHOBLAST giant cell represents one possible end point of the trophectoderm multilineage pathway (l-4). Giant cells are characteristic of rodent placentation (5, 6) . These cell types originate via a process referred to as endoreduplication, continued DNA replication without mitosis (7), and are endowed with a number of specialized functions, including the biosynthesis of steroid and polypeptide hormones (4, 8) . Trophoblast hormones act as signals coordinating the requisite metabolic adjustments in maternal and embryonic environments. Consequently, stage-specific changes in the behavior of trophoblast giant cells are necessary and are likely to correspond to precise needs of the developing embryo.
The stage-specific nature of trophoblast giant cell behavior is best illustrated by the patterns of trophoblast giant cell expression of members of the placental PRL gene family (8) . Six members of the placental PRL gene family have been identified: placental lactogen-I (PL-I), PL-II, PRL-like protein-A (PLP-A), PLP-B, PLP-C, and PL-I variant (PL-Iv) (8). Giant cell PL-I expression is initiated shortly after implantation (9). PL-II production begins at midgestation (between days lo-12 of gestation) and continues throughout the remainder of pregnancy (9, 10). PL-I production ceases by day 12 of gestation, shortly after the initiation of PL-II expression (9). Production of PLP-A, PLP-C, and PL-Iv begins sometime after day 13 of gestation and continues within a subpopulation of giant cells until term (10-13). Giant cells do not express 15) . Temporally, PL-I is an early marker, PL-II is an intermediate marker, and PLP-A, PLP-C, and PLIv are late markers of trophoblast giant cell differentiation. Factors responsible for the stage-specific progression of the trophoblast giant cell differentiation program are unknown.
The establishment of the Rcho-1 cell line has permitted investigations into the control of trophoblast giant cell differentiation. The Rcho-1 cell line was derived from a transplantable rat choriocarcinoma (16). The value of this cell line is that it contains both proliferative and differentiated trophoblast cells (16). Differentiation appears to be restricted to the trophoblast giant cell lineage and includes expression of members of the placental PRL gene family (16). In this study, we report the development of culture conditions sufficient to direct the Rcho-1 cells to proliferate or differentiate. Furthermore, we show that in vitro Rcho-1 cell differentiation progresses in discrete stages, recapitulating the pattern of differentiation observed for trophoblast giant cells in situ.
Materials and Methods

Reagents
Reagents for sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis were purchased from Bio-Rad (Richmond, CA). Nitrocellulose was purchased from Schleicher and Schuell (Keene, NH). cDNAs for members of the rat placental PRL family were generously provided by Dr. D. Linzer (PL-I; Northwestern University, Evanston, IL) (17) and Drs. M. Duckworth and H. Friesen (FL-II, and PLP-A; University of Manitoba, Winnipeg, Canada) (18, 19) . A cDNA to PLP-C was generated in this laboratory (13 Burton (21) and normalized to cell number, as determined with the aid of a hemocytometer.
Western blot analysis
Relative concentrations of PL-I, PL-II, and PLP-A protein released by Rcho-I cells during differentiation were estimated by electrophoresis and immunoblotting. Conditioned medium was collected from gestation day 11 trophoblast tissue explant cultures, as previously described (9), or from Rcho-1 cell cultures, concentrated lo-fold by acetone precipitation, and solubilized in treatment buffer. The concentrated samples were then separated by SDS-polyacrylamide gel electrophoresis in 12.5% gels under reducing conditions (22) and electrophoretically transferred to nitrocellulose (23). FL-II was detected with an antipeptide antiserum directed to amino acids 56-70 of rat PL-II (24). PLP-A was detected with an antiserum generated against recombinant PLP-A (25). Both antisera have been validated for use in Western blot analyses. The generation of an antiserum to PL-I is described below. Detection of PIIv-and PLP-C-immunoreactive proteins with specific antisera (11, 12) was equivocal and is not shown. The processing and development of nitrocellulose membranes for reactivity with antisera were performed as previously described (26).
Holtzman rats were obtained from Harlan Sprague-Dawley (lndianapolis, IN). The animals were housed in an environmentally controlled facilitv, with lights on from 0600-2000 h, and allowed free access to food and water. Timed pregnancies were generated by cohabitation of female and male rats (Harlan) and daily examination of vaginal smears. The presence of a copulatory plug or sperm in the vaginal smear was designated day 0 of pregnancy. Rat placental tissues were dissected as previously described (9) and used as a control for characterization of the PL-I antipeptide antibodies (see below). Protocols for the care and use of animals were approved by the University of Kansas Animal Care and Use Committee.
Maintenance
of the Rcho-1 cell line
The Rcho-I cell line was routinely maintained in subconfluent conditions with either RPMI-1640 or NCTC-135 culture medium supplemented with lo-20% FBS, as previously reported (16). Differentiation was induced by growing the cells to confluence in 20% FBS-supplemented culture medium and then replacing the serum supplementation with donor horse serum (HS; l-10%).
Assessment of Rcho-1 cell proliferation
The effects of FBS and HS on Rcho-1 cell proliferation were investigated. Cultures were established by plating 500 cells/well in 24-well plates (day 0). Treatments (various concentrations of FBS or HS) were added at the time of plating. Culture medium and treatments were replaced at 2-day intervals. Cultures were maintained for 7 days, followed by assessment of cell proliferation, as previously described (20). Briefly, at the termination of~culture, cell monolayers were rinsed with PBS 110 mM sodium ohosohate CDH 7.21 and 150 mu NaCll and stained with&crystal violet (300 ;l/well, 5% formalin, 50% ethanol, 150 mM NaCI, and 0.5% crystal violet) for 10 min. Monolayers were extensively washed in tap water to remove excess stain before elution with 1 ml ethylene glycol. Cell density was estimated by monitoring absorbance of the eluate at 600 nm.
DNA synthesis and content during trophoblust differentiation DNA synthesis in proliferating and differentiating Rcho-1 cells was determined by the measurement of the incorporation of [3H]thymidine into DNA. Rcho-1 cells were plated at 13,333 cells/cm' in 20% FBS-RPM1 (day 0). Medium was changed every day. After day 2 of culture, medium was changed to 10% HS-RPMI. On each day, selected cultures were pulsed with [sH]thymidine for 4 h, and the amount of [3H] thymidine incorporated into DNA was measured, as previously described (20) . Briefly, monolayers were washed twice with ice-cold PBS, twice with 10% trichloroacetic acid, and once with ethanol-ether (3:l). Cellular residues were solubilized in 2 ml 0.2 N sodium hydroxide. After a 20-min incubation at room temperature, radioactivity was measured by liquid scintillation counting. Replicate cultures were harvested daily during the 12-day culture period and enzymatically dissociated, and cell counts were performed with the aid of a hemocytometer.
The total cellular DNA content was measured from Rcho-1 cells on days 2 and 9 of culture. Cultures were established as described above and maintained in 20% FBS-NCTC until day 3, when medium was changed to 10% HS-NCTC. Total cellular DNA was estimated by the Generation and characterization of antipeptide antibodies to PL-I Antibodies were made to a 19-amino acid peptide representing amino acids 1-19 (N-terminal) of rat FL-I and to a IS-amino acid peptide representing amino acids 51-65 (internal) of rat PL-I (27). Selection of peptide antigens was based on our past success in generating antibodies to the N-termini of other members of the placental PRL family (11, 12) and the identification of a hydrophilic region of the PL-I amino acid sequence that was significantly different from the related protein, PL-Iv (amino acids 51-65) (11). The N-terminal and internal peptides were synthesized as carboxyl-terminal amides by Multiple Peptide Systems (San Diego, CA) and the University of Kansas Biotechnology Support Facility, respectively. The N-terminal peptide was synthesized with a cysteine at its carboxyl-terminus, whereas the internal peptide contained an endogenous cysteine at its N-terminus. The synthetic peptides were coupled to keyhole limpet hemocyanin and used to immunize New Zealand White rabbits (Camm Research Laboratories, Wayne, NJ), as previously described (24, 28) . Antipeptide antisera were characterized by enzyme-linked immunoassays and Western blot analyses (24, 26) .
Northern blot analysis
Expression of mRNAs for members of the placental PRL gene family was monitored by Northern blot analysis (16, 29) . PL-I, PL-II, PLP-A, PLP-C, and @-tubulin cDNAs were used in the analysis (13, (17) (18) (19) 30) . Total cellular RNA was isolated, separated on agarose gels, and blotted onto nitrocellulose, as previously described (9, 16). Prehybridization, hybridization, and posthybridization treatment of filters were carried out as previouslv described (16, 29) . After hvbridization, filters were dried and processed for autoradiography using-Kodak X-Omat AR x-ray film (Eastman Kodak. Rochester. NY) at -80 C. A cDNA to B-tubulin (30) was used as a control to evaluate the integrity of mRNAs from different treatments.
Results
Maintenance
and manipulation of Rcho-1 cell phenotypes
Rcho-1 cells were routinely maintained at subconfluent conditions in either RPMI-1640 or NCTC-135 culture medium supplemented with lo-20% FBS. The cells grew more vigorously in RPMI-1640, but at the expense of poor pH regulation. Cellular proliferation was dependent upon the presence of some factors present in FBS (Fig. 1) . The effects TROPHOBLAST CELL DIFFERENTIATION Endo. 1994 Voll34. No 6 of sera on proliferation were determined by measuring absorbance (600 nm) of eluates of crystal violet-stained Rcho-1 cells. In this assay, cell number is positively correlated with absorbance of the cellular eluates and is linear between 500-64,000 cells/well (correlation coefficient = 0.99; P < O.OOl), and the intraassay variation is 10.8%. HS was sufficient for the maintenance of Rcho-1 cell viability and the facilitation of Rcho-1 cell differentiation, but was not sufficient for maintenance of Rcho-1 cell proliferation (Fig. 1) . The addition of HS to Rcho-1 cells cultured in FBS did not significantly affect FBS-stimulated Rcho-1 cell proliferation (Fig. 1) . Differentiation was induced by growing Rcho-1 cells to confluence in FBS-supplemented culture medium and then replacing the serum supplementation with HS (l-10%). In these cultures, confluence was achieved between days 2-3 of culture, and Rcho-1 cells were routinely shifted from FBSto HS-containing medium on day 3 of culture. Rcho-1 cells, independent of their differentiation state, could not tolerate the absence of serum for more than 48 h. Figure 2 shows the time course of DNA synthesis in differentiating Rcho-1 cultures and provides a comparison of cellular DNA content in day 2 (proliferating) US. day 9 (differentiating) cultures. , triplicate 25-cm* flasks were used to determine cell number and total DNA content on days 2 and 9 of culture. The data are expressed as the ratio of total DNA content to cell number. Fig. 2 . At the outset of the culture period (days 1 and 2), Rcho-1 cells showed a high level of DNA synthesis. As the culture period progressed, DNA synthesis declined from days 2-4 and then was maintained at approximately 20-25s of the peak level through the remainder of the culture period (Fig. 2) . DNA content per cell increased significantly from days 2-9 of culture (by Student's t test, P < 0.01; Fig. 2 ). The continued synthesis of DNA throughout the culture period in the absence of increased cell numbers and the increase in DNA content per cell during the culture period are indicative of endoreduplication.
Validation of PL-I antipeptide antibodies
Western blot analysis of PL-I produced by day 11 placental tissue and Rcho-1 cells with antipeptide antibodies generated against the N-terminal 19 amino acids of rat PL-I is shown in Fig. 3 Conditioned medium generated by placental explants isolated from day 11 of gestation (P) or differentiated Rcho-1 cells (C) was concentrated lo-fold, separated by SDS-polyacrylamide gel electrophoresis in 12.5% gels, electrophoretically transferred to nitrocellulose, and probed with antipeptide antibodies generated against the N-terminal 19 amino acids of rat PL-I. Lanes A and C, Day 11 placental explant conditioned medium; lanes B and D, Rcho-1 cell-conditioned medium. Lanes A and B were exposed to the PL-I antibodies; lanes C and D were exposed to the PL-I antibodies saturated with the N-terminal PL-I peptide antigen. Please note the similarity of the migration of PL-I produced by placental and Rcho-1 cells. Mol wt standards (X10m3) are shown.
cells was slightly more heterogeneous. The specificity of the immunoreactions was demonstrated by competition with excess N-terminal PL-I peptide (Fig. 3) . Furthermore, Westem blot analyses performed with antibodies directed to the N-terminus of rat PL-I were virtually identical to Western blots performed with antibodies made against the whole PL-I protein (9, 16) (data not shown). Antibodies were generated to the internal domain of rat PL-I (amino acids 51-65); however, these antibodies did not recognize PL-I in Western blot analyses of conditioned medium from day 11 placental tissue or Rcho-1 cells.
Expression of members of the placental PRL gene family during trophoblust cell differentiation
Expression of members of the placental PRL gene family were examined by Western and Northern blot analyses (Figs.  4 and 5) . The electrophoretic characteristics of the proteins and their mRNAs were consistent with previously determined characteristics of these proteins and mRNAs from the rat placenta, except for the PLP-A protein (16). As previously noted (16), Rcho-1 PLP-A is secreted primarily as a 33-kDa species, whereas placental PLP-A is secreted as 29-and 33-kDa species. During the course of in vitro Rcho-1 cell differentiation, PL-I expression was detected first, sequentially followed by the expression of PL-II, PLP-A, and PLP-C. The temporal pattern of expression of members of the placental PRL family determined by Western blot analysis matched the pattern determined by Northern blot analyses (Figs. 4  and 5) . Detection of PLP-C protein was below the limits of sensitivity of our Western blot analysis. P-Tubulin mRNA . Medium was changed to 1% HS-NCTC when the cultures became confluent. Conditioned medium was collected every 2 days, concentrated lo-fold, separated by SDS-polyacrylamide gel electrophoresis in 12.5% gels, electrophoretically transferred to nitrocellulose, and probed with antibodies to rat PL-I, rat PL-II, or recombinant PLP-A. Please note that the pattern of temporal expression matches the pattern seen by Northern blot analyses (see Fig. 5 ). PLP-C could not be detected in conditioned medium. Mol wt standards (X10e3) are shown.
concentrations showed a slight decrease as the Rcho-1 cells progressed from proliferation to differentiation, consistent with our previous report (16). by the precise developmental appearance of trophoblast giant cells expressing unique phenotypes. The parallel differentiation pathway would be characterized by the developmental appearance of distinct populations of trophoblast giant cells with phenotypes restricted to the expression of only one member of the placental PRL family. The sequential differentiation pathway would be characterized by the systematic acquisition or loss of expression of multiple members of the placental PRL gene family by an individual trophoblast giant cell, The identification of individual giant cells capable of expressing multiple members of the placental PRL family (32-34) would support the existence of a sequential pathway of trophoblast giant cell development. A sequential differentiation pathway has also been postulated for human trophoblast cells (35, 36) . Human trophoblast cell differentiation is characterized by the incremental acquisition of expression of the a-subunit of CG, followed by the P-subunit of CG, and finally PL (35, 36) . The continued expression of PL-I by Rcho-1 cells in vitro is in contrast to the regulation of this gene during the normal development of the placenta in viva (Ref. 8 and the present study; see Fig. 6 ). In vim PL-I and PL-II coexpression is limited to approximately a 24-h interval during midgestation (9). The factors responsible for the midgestation termination of PL-I expression are yet to be identified. Yamaguchi and co-workers (37) have provided evidence that progesterone decreases PL-I secretion by primary cultures of placental cells. Based on observations from our laboratory, a role for progesterone in the termination of PL-I expression during midgestation is not straightforward. Trophoblast giant cells from the normal rat placenta or derived from the Rcho-1 cell line produce progesterone (38, 39) , and the production of progesterone increases during trophoblast giant cell differentiation in parallel with increases in PL-I expression (Ref. 39 and the present study), the opposite of what one might predict. Furthermore, the addition of progesterone or the progesterone receptor antagonist RU486 to Rcho-1 cells has no significant affect on PL-I expression (Prohaska, D., G. Hamlin, and M. Soares, unpublished results). We hypothesize the termination of PL-I expression during midgestation is likely to be controlled by signals unique to the in viva condition. Involvement of progesterone in the termination of PL-I expression may be indirect, involving cells other than those of the trophoblast giant cell lineage. Alternatively, the failure of Rcho-1 cells to terminate PL-I expression may reflect an aberration in the cell line.
Rcho-1 cell differentiation most closely resembles differentiation occurring in the junctional zone of the chorioallantoic placenta and may represent a wild-type phenotype (4). Trophoblast giant cells located in the labyrinth zone only express PL-II, suggesting the importance of environmental modulation or the existence of distinct trophoblast giant cell lineages (4).
Normal trophoblast cells do not proliferate in vitro; they spontaneously differentiate (1, 2, 7, 40) . The classic interpretation of the control of trophoblast cell growth and differentiation is that growth is dependent upon in situ signals, and removal of these in situ signals results in spontaneous differentiation (1, 2, 7, 40) . In contrast, Rcho-1 cells apparently possess specific mutations, enabling them to proliferate under a variety of in vivo and in vitro conditions (Refs. 16, 41 , and 42 and the present study). The nature of the aberration(s) in the Rcho-1 cells is unknown. Nonetheless, these cells can be manipulated to exit the proliferative state and progress along the trophoblast giant cell lineage in a manner resembling normal trophoblast cells maturing in situ. An arrest of proliferation appears to be the first step in the trophoblast giant cell differentiation pathway. Similar relationships between proliferation and differentiation have been identified for other cell types, such as adipose, epidermis, bone, and muscle (43-46).
The Rcho-1 cell line offers an attractive in vitro model for the identification of signals initiating and maintaining the differentiated phenotype. Cancer cells, such as those represented by the Rcho-1 cell line, are caricatures of normal development and represent important resources for dissecting regulatory mechanisms (47,48). The key is in identifying which regulatory mechanisms are characteristic of normal development and which correspond to the transformed phenotype.
